Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

NCT06373146 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06373146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06373146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
April 24, 2024
Completion date
April 2, 2026
Enrollment
392 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

obesity